Functional Analysis Of Relapse Predictive Genes In Wilms Tumour
Funder
National Health and Medical Research Council
Funding Amount
$571,311.00
Summary
Wilms tumor is a paediatric kidney cancer, the most common abdominal tumour seen in children. About 20% of Wilms tumour patients have relapsing fatal tumours. We have found two genes that mark tumours which relapse: C-EBPB and CLK1. Characterization of C-EBPB and CLK1 will yield new information regarding the mechanisms underlying development and progression of Wilms tumours, leading to improved treatment for Wilms tumor patients. Both C-EBPB and CLK1 may also have roles in other human cancers.
Genomic And Proteomic Dissection Of The Molecular Basis Of Kidney Development.
Funder
National Health and Medical Research Council
Funding Amount
$454,582.00
Summary
The number of nephrons present in the human adult kidney can vary by threefold. This is likely to be due to slight variations in the rate of nephron formation during development. Evidence is mounting that a reduced number of nephrons can predispose to renal failure later in life in response to stresses such as hypertension or substance abuse. 80,000 new cases of end stage renal failure occur each year in the US, with 25% of these related to hypertension and therefore possibly linked to a low nep ....The number of nephrons present in the human adult kidney can vary by threefold. This is likely to be due to slight variations in the rate of nephron formation during development. Evidence is mounting that a reduced number of nephrons can predispose to renal failure later in life in response to stresses such as hypertension or substance abuse. 80,000 new cases of end stage renal failure occur each year in the US, with 25% of these related to hypertension and therefore possibly linked to a low nephron number. While it is known that the kidney arises through a series of reciprocal inductive events between the metanephric mesenchyme and the ureteric bud, a better understanding of the molecular basis of these events is needed to understand what dictates nephron endowment. The Wilms tumour suppressor protein WT1 is not only mutated in some cases of the childhood kidney cancer, Wilms tumour, but is also critical for the normal development of the metanephros, as demonstrated by knockout experiments in mice. One of the earliest genes expressed in the metanephric mesenchyme, WT1 is thought to prevent this tissue from dying before differentiation, directing it to form the kidney and, postnatally, regulating normal podocyte function. Although known to be a nuclear regulatory protein, the genes directly regulated by WT1 have not been clearly or convincingly delineated. This study aims to directly screen for changes to gene expression and protein production levels induced by WT1. To do so, an array approach unique in its use of a specific array set derived from developing kidney will be used. In concert, additional specific clone sets derived from mouse kidney prior and post the commencement of nephron formation will be constructed and analysed. As WT1 is a nuclear protein involved in splicing, this study will involve a parallel investigation at a proteomic level of changes in spliceosomal proteins in response to changes in WT1.Read moreRead less
Investigating Immune Regulation In The Tumour Microenvironment
Funder
National Health and Medical Research Council
Funding Amount
$288,650.00
Summary
Suppressive factors made by cells of the immune system or cancers themselves and immune regulatory T cells inhibit an effective anti-tumour response. My project aims to investigate the mechanism by which these factors and cells mediate their suppressive function. Understanding these processes in the cancer environment will allow the design of more effective cancer therapies.
The Oncogenic Function Of A Histone H3K9 Demethylase And Its Contribution To The Aggressive Malignant Phenotype Of Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$762,501.00
Summary
In contrast to the significant improvements in the treatment of acute lymphocytic leukaemia, advances in acute myeloid leukaemia (AML) therapy have been limited. The difficulty in treating AML is thought to arise from a drug-resistant subpopulation of leukaemic stem cells (LSC) that are capable of reinitiating disease after chemotherapy. This project will characterise a key regulator of LSC and provide insights into an important oncogenic process that gives rise to the aggressive and often fatal ....In contrast to the significant improvements in the treatment of acute lymphocytic leukaemia, advances in acute myeloid leukaemia (AML) therapy have been limited. The difficulty in treating AML is thought to arise from a drug-resistant subpopulation of leukaemic stem cells (LSC) that are capable of reinitiating disease after chemotherapy. This project will characterise a key regulator of LSC and provide insights into an important oncogenic process that gives rise to the aggressive and often fatal AML.Read moreRead less